<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p152" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_152{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_152{left:306px;bottom:30px;}
#t3_152{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_152{left:346px;bottom:30px;}
#t5_152{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_152{left:517px;bottom:30px;}
#t7_152{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_152{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_152{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_152{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_152{left:35px;bottom:777px;letter-spacing:0.12px;word-spacing:0.07px;}
#tc_152{left:512px;bottom:785px;letter-spacing:0.1px;}
#td_152{left:557px;bottom:777px;}
#te_152{left:35px;bottom:754px;letter-spacing:0.08px;word-spacing:0.11px;}
#tf_152{left:499px;bottom:761px;letter-spacing:-0.01px;}
#tg_152{left:35px;bottom:713px;letter-spacing:0.1px;word-spacing:-1.01px;}
#th_152{left:35px;bottom:690px;letter-spacing:0.07px;word-spacing:0.12px;}
#ti_152{left:35px;bottom:667px;letter-spacing:0.14px;word-spacing:0.05px;}
#tj_152{left:35px;bottom:645px;letter-spacing:0.05px;word-spacing:0.14px;}
#tk_152{left:183px;bottom:653px;}
#tl_152{left:194px;bottom:645px;letter-spacing:0.3px;word-spacing:-0.1px;}
#tm_152{left:440px;bottom:653px;letter-spacing:-0.01px;}
#tn_152{left:463px;bottom:645px;letter-spacing:0.04px;word-spacing:0.14px;}
#to_152{left:35px;bottom:622px;letter-spacing:0.12px;word-spacing:-1.16px;}
#tp_152{left:462px;bottom:629px;letter-spacing:-0.01px;}
#tq_152{left:484px;bottom:622px;letter-spacing:-0.08px;word-spacing:-0.95px;}
#tr_152{left:35px;bottom:599px;letter-spacing:0.09px;word-spacing:0.1px;}
#ts_152{left:35px;bottom:575px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tt_152{left:35px;bottom:552px;letter-spacing:0.07px;word-spacing:0.12px;}
#tu_152{left:35px;bottom:529px;letter-spacing:0.04px;word-spacing:-0.47px;}
#tv_152{left:484px;bottom:536px;letter-spacing:-0.01px;}
#tw_152{left:506px;bottom:529px;letter-spacing:0.33px;word-spacing:-1.34px;}
#tx_152{left:35px;bottom:506px;letter-spacing:0.06px;word-spacing:0.12px;}
#ty_152{left:35px;bottom:482px;letter-spacing:0.12px;word-spacing:0.07px;}
#tz_152{left:35px;bottom:459px;letter-spacing:0.14px;word-spacing:0.05px;}
#t10_152{left:35px;bottom:436px;letter-spacing:-0.05px;}
#t11_152{left:35px;bottom:396px;letter-spacing:0.16px;word-spacing:0.03px;}
#t12_152{left:35px;bottom:372px;letter-spacing:0.16px;word-spacing:0.03px;}
#t13_152{left:35px;bottom:349px;letter-spacing:0.05px;word-spacing:-0.11px;}
#t14_152{left:35px;bottom:326px;letter-spacing:0.18px;word-spacing:-0.12px;}
#t15_152{left:35px;bottom:303px;letter-spacing:0.12px;word-spacing:0.07px;}
#t16_152{left:35px;bottom:280px;letter-spacing:0.11px;word-spacing:0.07px;}
#t17_152{left:35px;bottom:256px;letter-spacing:-0.13px;}
#t18_152{left:119px;bottom:264px;letter-spacing:0.1px;}
#t19_152{left:164px;bottom:256px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1a_152{left:35px;bottom:233px;letter-spacing:0.04px;word-spacing:-0.48px;}
#t1b_152{left:425px;bottom:241px;letter-spacing:-0.62px;}
#t1c_152{left:446px;bottom:233px;letter-spacing:0.14px;word-spacing:0.07px;}
#t1d_152{left:35px;bottom:210px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1e_152{left:35px;bottom:187px;letter-spacing:0.03px;}
#t1f_152{left:35px;bottom:148px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1g_152{left:35px;bottom:124px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1h_152{left:35px;bottom:101px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1i_152{left:35px;bottom:78px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1j_152{left:35px;bottom:55px;letter-spacing:0.03px;word-spacing:-0.72px;}
#t1k_152{left:618px;bottom:777px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1l_152{left:618px;bottom:754px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1m_152{left:618px;bottom:731px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1n_152{left:618px;bottom:707px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1o_152{left:618px;bottom:684px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1p_152{left:618px;bottom:661px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1q_152{left:618px;bottom:638px;letter-spacing:0.15px;word-spacing:0.06px;}
#t1r_152{left:1105px;bottom:645px;letter-spacing:-0.01px;}
#t1s_152{left:618px;bottom:614px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1t_152{left:618px;bottom:591px;letter-spacing:0.19px;}
#t1u_152{left:618px;bottom:568px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1v_152{left:618px;bottom:529px;letter-spacing:0.04px;word-spacing:-0.43px;}
#t1w_152{left:618px;bottom:506px;letter-spacing:-0.07px;}
#t1x_152{left:660px;bottom:513px;}
#t1y_152{left:671px;bottom:506px;letter-spacing:0.02px;word-spacing:-0.64px;}
#t1z_152{left:1000px;bottom:513px;}
#t20_152{left:1011px;bottom:506px;letter-spacing:0.19px;}
#t21_152{left:618px;bottom:482px;letter-spacing:0.08px;word-spacing:-0.13px;}
#t22_152{left:618px;bottom:459px;letter-spacing:0.1px;word-spacing:0.08px;}
#t23_152{left:842px;bottom:467px;letter-spacing:-0.01px;}
#t24_152{left:865px;bottom:459px;letter-spacing:0.1px;word-spacing:0.09px;}
#t25_152{left:618px;bottom:436px;letter-spacing:0.13px;word-spacing:0.06px;}
#t26_152{left:618px;bottom:413px;letter-spacing:0.08px;word-spacing:0.11px;}
#t27_152{left:618px;bottom:390px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t28_152{left:923px;bottom:390px;}
#t29_152{left:939px;bottom:390px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2a_152{left:618px;bottom:366px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2b_152{left:618px;bottom:343px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2c_152{left:618px;bottom:320px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2d_152{left:989px;bottom:320px;}
#t2e_152{left:1005px;bottom:320px;letter-spacing:0.17px;word-spacing:0.01px;}
#t2f_152{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:-1.05px;}
#t2g_152{left:618px;bottom:273px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2h_152{left:618px;bottom:250px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2i_152{left:985px;bottom:250px;}
#t2j_152{left:1001px;bottom:250px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t2k_152{left:618px;bottom:227px;letter-spacing:0.06px;word-spacing:-0.43px;}
#t2l_152{left:618px;bottom:204px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2m_152{left:1151px;bottom:211px;letter-spacing:-0.01px;}
#t2n_152{left:618px;bottom:163px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2o_152{left:618px;bottom:140px;letter-spacing:0.07px;word-spacing:-0.02px;}
#t2p_152{left:618px;bottom:117px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2q_152{left:618px;bottom:94px;letter-spacing:0.14px;word-spacing:-1.19px;}
#t2r_152{left:944px;bottom:94px;}
#t2s_152{left:958px;bottom:94px;letter-spacing:0.1px;word-spacing:-1.15px;}
#t2t_152{left:618px;bottom:71px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2u_152{left:825px;bottom:71px;}
#t2v_152{left:841px;bottom:71px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2w_152{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_152{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_152{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_152{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_152{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_152{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_152{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_152{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_152{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts152" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg152Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg152" style="-webkit-user-select: none;"><object width="1210" height="935" data="152/152.svg" type="image/svg+xml" id="pdf152" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_152" class="t s0_152">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_152" class="t s1_152">© </span>
<span id="t3_152" class="t s0_152">(NCCN </span>
<span id="t4_152" class="t s1_152">© </span>
<span id="t5_152" class="t s0_152">), All rights reserved. NCCN Guidelines </span>
<span id="t6_152" class="t s1_152">® </span>
<span id="t7_152" class="t s0_152">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_152" class="t s2_152">NCCN Guidelines Version 4.2024 </span>
<span id="t9_152" class="t s2_152">Head and Neck Cancers </span>
<span id="ta_152" class="t s3_152">MS-11 </span>
<span id="tb_152" class="t s4_152">cancers of the oral cavity, oropharynx, larynx, or hypopharynx. </span>
<span id="tc_152" class="t s5_152">134,135 </span>
<span id="td_152" class="t s4_152">A </span>
<span id="te_152" class="t s4_152">combined analysis of data from the two trials has been done. </span>
<span id="tf_152" class="t s5_152">136 </span>
<span id="tg_152" class="t s4_152">The US Intergroup trial (RTOG 9501) randomly assigned patients with two </span>
<span id="th_152" class="t s4_152">or more involved nodes, positive margins, or extracapsular nodal spread </span>
<span id="ti_152" class="t s4_152">of tumor to receive standard postoperative RT or the same RT plus </span>
<span id="tj_152" class="t s4_152">cisplatin (100 mg/m </span>
<span id="tk_152" class="t s5_152">2 </span>
<span id="tl_152" class="t s4_152">every 3 weeks for three doses). </span>
<span id="tm_152" class="t s5_152">135 </span>
<span id="tn_152" class="t s4_152">Note that </span>
<span id="to_152" class="t s4_152">long-term results from RTOG 9501 have been published. </span>
<span id="tp_152" class="t s5_152">137 </span>
<span id="tq_152" class="t s4_152">The European </span>
<span id="tr_152" class="t s4_152">trial (EORTC 22931) was designed using the same chemotherapy </span>
<span id="ts_152" class="t s4_152">treatment and similar RT dosing but also included as high-risk factors the </span>
<span id="tt_152" class="t s4_152">presence of perineural or vascular embolism and nodal involvement at </span>
<span id="tu_152" class="t s4_152">levels IV and V from an oral cavity or oropharyngeal cancer. </span>
<span id="tv_152" class="t s5_152">134 </span>
<span id="tw_152" class="t s4_152">The RTOG </span>
<span id="tx_152" class="t s4_152">trial showed statistically significant improvement in locoregional control </span>
<span id="ty_152" class="t s4_152">and disease-free survival (DFS) but not OS, whereas the EORTC trial </span>
<span id="tz_152" class="t s4_152">found significant improvement in survival and the other outcome </span>
<span id="t10_152" class="t s4_152">parameters. </span>
<span id="t11_152" class="t s4_152">To better define risk, a combined analysis of prognostic factors and </span>
<span id="t12_152" class="t s4_152">outcome from the RTOG 9501 and EORTC 22931 trials was performed. </span>
<span id="t13_152" class="t s4_152">This analysis showed that patients in both trials with extranodal extension </span>
<span id="t14_152" class="t s4_152">of tumor and/or positive resection margins benefited from the addition of </span>
<span id="t15_152" class="t s4_152">cisplatin to postoperative RT. For those with multiple involved regional </span>
<span id="t16_152" class="t s4_152">nodes without extranodal extension, there was no survival </span>
<span id="t17_152" class="t s4_152">advantage. </span>
<span id="t18_152" class="t s5_152">136,137 </span>
<span id="t19_152" class="t s4_152">However, it is important to note that the combined </span>
<span id="t1a_152" class="t s4_152">analysis was considered exploratory by the authors. </span>
<span id="t1b_152" class="t s5_152">136 </span>
<span id="t1c_152" class="t s4_152">These publications </span>
<span id="t1d_152" class="t s4_152">form the basis for the NCCN recommendations regarding adjuvant </span>
<span id="t1e_152" class="t s4_152">treatment. </span>
<span id="t1f_152" class="t s4_152">In NCCN Member Institutions, most patients with extranodal extension </span>
<span id="t1g_152" class="t s4_152">with or without positive surgical margins receive adjuvant </span>
<span id="t1h_152" class="t s4_152">chemoradiotherapy after surgery. The presence of other adverse </span>
<span id="t1i_152" class="t s4_152">pathologic risk factors—multiple positive nodes (without extranodal </span>
<span id="t1j_152" class="t s4_152">extension), perineural invasion, vascular invasion, lymphatic invasion, pT3 </span>
<span id="t1k_152" class="t s4_152">or pT4 primary, and oral cavity or oropharyngeal primary cancers with </span>
<span id="t1l_152" class="t s4_152">positive level IV or V nodes—are generally established indications for </span>
<span id="t1m_152" class="t s4_152">postoperative RT. Because patients with these other adverse pathologic </span>
<span id="t1n_152" class="t s4_152">features were also included in the EORTC 22931 trial that showed a </span>
<span id="t1o_152" class="t s4_152">survival advantage for patients receiving cisplatin concurrently with </span>
<span id="t1p_152" class="t s4_152">postoperative RT compared to RT alone, the NCCN Panel added a </span>
<span id="t1q_152" class="t s4_152">recommendation to consider chemoradiation for these features. </span>
<span id="t1r_152" class="t s5_152">134 </span>
<span id="t1s_152" class="t s4_152">Performance status (PS) and physiologic reserve should be taken into </span>
<span id="t1t_152" class="t s4_152">consideration before recommending postoperative concurrent </span>
<span id="t1u_152" class="t s4_152">chemoradiotherapy in patients with high-risk pathology. </span>
<span id="t1v_152" class="t s4_152">In a randomized phase III trial from a single institution in India, cisplatin 30 </span>
<span id="t1w_152" class="t s4_152">mg/m </span>
<span id="t1x_152" class="t s5_152">2 </span>
<span id="t1y_152" class="t s4_152">weekly was compared to cisplatin 100 mg/m </span>
<span id="t1z_152" class="t s5_152">2 </span>
<span id="t20_152" class="t s4_152">every 3 weeks, when </span>
<span id="t21_152" class="t s4_152">given concurrently with RT, in 300 patients with locally advanced SCCHN </span>
<span id="t22_152" class="t s4_152">(93% in the adjuvant setting). </span>
<span id="t23_152" class="t s5_152">138 </span>
<span id="t24_152" class="t s4_152">Two-year locoregional control was </span>
<span id="t25_152" class="t s4_152">superior in patients randomized to receive cisplatin once every 3 weeks </span>
<span id="t26_152" class="t s4_152">(73.1%), compared to patients randomized to receive weekly cisplatin </span>
<span id="t27_152" class="t s4_152">(58.5%) (HR, 1.76; 95% CI, 1.11–2.79; </span><span id="t28_152" class="t s6_152">P </span><span id="t29_152" class="t s4_152">= .014). However, patients </span>
<span id="t2a_152" class="t s4_152">randomized to receive cisplatin once every 3 weeks developed more </span>
<span id="t2b_152" class="t s4_152">severe acute toxicities, compared to patients randomized to receive </span>
<span id="t2c_152" class="t s4_152">weekly cisplatin (84.6% vs. 71.6%, respectively; </span><span id="t2d_152" class="t s6_152">P </span><span id="t2e_152" class="t s4_152">= .006). The acute </span>
<span id="t2f_152" class="t s4_152">adverse events that were significantly more likely to have been reported in </span>
<span id="t2g_152" class="t s4_152">patients who received cisplatin once every 3 weeks were hyponatremia, </span>
<span id="t2h_152" class="t s4_152">leukopenia, neutropenia, and lymphocytopenia ( </span><span id="t2i_152" class="t s6_152">P </span><span id="t2j_152" class="t s4_152">&lt; .001 for all). A </span>
<span id="t2k_152" class="t s4_152">schedule using cisplatin at 50 mg intravenously (IV) weekly has also been </span>
<span id="t2l_152" class="t s4_152">shown to improve survival in the adjuvant setting in a randomized trial. </span>
<span id="t2m_152" class="t s5_152">139 </span>
<span id="t2n_152" class="t s4_152">In a randomized phase II/III study from India in which patients with locally </span>
<span id="t2o_152" class="t s4_152">advanced SCCHN and who were cisplatin-ineligible received RT alone or </span>
<span id="t2p_152" class="t s4_152">concurrently with docetaxel (N = 356), 2-year DFS (42.0% vs. 30.3%, </span>
<span id="t2q_152" class="t s4_152">respectively; HR, 0.67, 95% CI, 0.52–0.87; </span><span id="t2r_152" class="t s6_152">P </span><span id="t2s_152" class="t s4_152">= .002), median OS (25.5 vs. </span>
<span id="t2t_152" class="t s4_152">15.3 months, respectively; </span><span id="t2u_152" class="t s6_152">P </span><span id="t2v_152" class="t s4_152">= .035), and 2-year OS (50.8% vs. 41.7%, </span>
<span id="t2w_152" class="t s7_152">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
